Market Cap 414.63M
Revenue (ttm) 266.27M
Net Income (ttm) -50.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.94%
Debt to Equity Ratio -7.80
Volume 2,343,300
Avg Vol 1,053,056
Day's Range N/A - N/A
Shares Out 64.69M
Stochastic %K 56%
Beta 0.97
Analysts Strong Sell
Price Target $19.40

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 949 284 4555
Address:
520 Newport Center Drive, Suite 1200, Newport Beach, United States
dogDazeSummer
dogDazeSummer Nov. 6 at 1:56 PM
$EOLS financials looked great 26% float short. The clean report last night was enough to clear $10-then $12. What is the short thesis anyhow ?
0 · Reply
dixiebull
dixiebull Nov. 5 at 9:55 PM
$OPRA moved to 14.69, see if 14.50 can break again for aa move to 15 and 15.50 $CURR hit 3.03 and settled there, see if 3 holds for a move to 3.50/4 $EOLS earnings moved this to 8.15, see if 7.50 holdshere for a break of 8 to 8.50 $VTYX climbed to 9.24, see if 9 holds or a dip to 8.50 for a move to 10 $BTQ ran to 7.39 so see if 7 holds ow for a move to 7.50 and 8
0 · Reply
chivo12
chivo12 Nov. 5 at 5:13 PM
$EOLS Q3 revenue and earnings report after the market close today. Management conf call the first with new cfo at 430pm today. Three months ago, Q2 Jeuveau revenue was a disaster. Q2 Evolysse revenue was great, but not enough to offset the Jeuveau softness. My back of the envelope expectation for Q3 is $70M (J rev $56M and E rev $14M).
0 · Reply
jjmo1491
jjmo1491 Oct. 31 at 5:18 PM
$EOLS On watch, entry 6.17, looking for 20%+ swing over next 30 days.
1 · Reply
MoneyAndAdderall
MoneyAndAdderall Oct. 28 at 7:10 PM
$EOLS im under the water in this stock and I didn't get out on my 20% mental stop loss as I would usually, because still believe in the long term growth and return to profitability in 2026
0 · Reply
Allf2
Allf2 Oct. 28 at 9:02 AM
$EOLS double play
0 · Reply
Mandi63
Mandi63 Oct. 27 at 2:37 PM
$AEON their European partner is on the rise today..$EOLS LOOKING FOR UPDATES..
0 · Reply
Estimize
Estimize Oct. 23 at 11:03 AM
Wall St is expecting -0.16 EPS for $EOLS Q3 [Reporting 11/05 AMC] http://www.estimize.com/intro/eols?chart=historical&metric_name=eps&utm_c
0 · Reply
Mandi63
Mandi63 Oct. 20 at 5:48 PM
0 · Reply
Mandi63
Mandi63 Oct. 17 at 4:07 PM
0 · Reply
Latest News on EOLS
Evolus Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 16 hours ago

Evolus Reports Third Quarter 2025 Financial Results


Evolus to Participate in 2025 Stifel Healthcare Conference

Oct 28, 2025, 8:00 AM EDT - 9 days ago

Evolus to Participate in 2025 Stifel Healthcare Conference


Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:15 PM EDT - 3 months ago

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript


Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings

Jul 21, 2025, 5:20 PM EDT - 3 months ago

Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings


Evolysse™ Recognized in 2025 Shape Skin Awards

Jun 10, 2025, 8:00 AM EDT - 5 months ago

Evolysse™ Recognized in 2025 Shape Skin Awards


Evolus Announces Departure of its Chief Financial Officer

May 27, 2025, 4:15 PM EDT - 5 months ago

Evolus Announces Departure of its Chief Financial Officer


Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:13 PM EDT - 6 months ago

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript


Evolus Reports First Quarter 2025 Results

May 7, 2025, 4:05 PM EDT - 6 months ago

Evolus Reports First Quarter 2025 Results


Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 7 months ago

Evolus to Report First Quarter Financial Results on May 7, 2025


Evolus Announces Commercial Launch of Evolysse™

Apr 16, 2025, 8:00 AM EDT - 7 months ago

Evolus Announces Commercial Launch of Evolysse™


Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:18 PM EST - 8 months ago

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript


US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:45 PM EST - 9 months ago

US FDA approves Evolus' anti-wrinkle gels


Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Jan 14, 2025, 2:00 PM EST - 10 months ago

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25


Evolus Reports Third Quarter 2024 Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Evolus Reports Third Quarter 2024 Results


Evolus to Participate in Stifel 2024 Healthcare Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in Stifel 2024 Healthcare Conference


Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 10:22 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript


Evolus to Hold Investor Day on September 12, 2024

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Evolus to Hold Investor Day on September 12, 2024


dogDazeSummer
dogDazeSummer Nov. 6 at 1:56 PM
$EOLS financials looked great 26% float short. The clean report last night was enough to clear $10-then $12. What is the short thesis anyhow ?
0 · Reply
dixiebull
dixiebull Nov. 5 at 9:55 PM
$OPRA moved to 14.69, see if 14.50 can break again for aa move to 15 and 15.50 $CURR hit 3.03 and settled there, see if 3 holds for a move to 3.50/4 $EOLS earnings moved this to 8.15, see if 7.50 holdshere for a break of 8 to 8.50 $VTYX climbed to 9.24, see if 9 holds or a dip to 8.50 for a move to 10 $BTQ ran to 7.39 so see if 7 holds ow for a move to 7.50 and 8
0 · Reply
chivo12
chivo12 Nov. 5 at 5:13 PM
$EOLS Q3 revenue and earnings report after the market close today. Management conf call the first with new cfo at 430pm today. Three months ago, Q2 Jeuveau revenue was a disaster. Q2 Evolysse revenue was great, but not enough to offset the Jeuveau softness. My back of the envelope expectation for Q3 is $70M (J rev $56M and E rev $14M).
0 · Reply
jjmo1491
jjmo1491 Oct. 31 at 5:18 PM
$EOLS On watch, entry 6.17, looking for 20%+ swing over next 30 days.
1 · Reply
MoneyAndAdderall
MoneyAndAdderall Oct. 28 at 7:10 PM
$EOLS im under the water in this stock and I didn't get out on my 20% mental stop loss as I would usually, because still believe in the long term growth and return to profitability in 2026
0 · Reply
Allf2
Allf2 Oct. 28 at 9:02 AM
$EOLS double play
0 · Reply
Mandi63
Mandi63 Oct. 27 at 2:37 PM
$AEON their European partner is on the rise today..$EOLS LOOKING FOR UPDATES..
0 · Reply
Estimize
Estimize Oct. 23 at 11:03 AM
Wall St is expecting -0.16 EPS for $EOLS Q3 [Reporting 11/05 AMC] http://www.estimize.com/intro/eols?chart=historical&metric_name=eps&utm_c
0 · Reply
Mandi63
Mandi63 Oct. 20 at 5:48 PM
0 · Reply
Mandi63
Mandi63 Oct. 17 at 4:07 PM
0 · Reply
Mandi63
Mandi63 Oct. 17 at 1:39 PM
$AEON $5 -10 BUY $AEON PENDING BROAD FDA APPROVAL COMING LOW FLOAT NEW CEO WITH BIOTECH EXPERIENCE CEO BOUGHT $EOLS IS THEIR EUROPEAN PARTNER $SANA $FEMY $OSCR $FEMY
0 · Reply
Mandi63
Mandi63 Oct. 15 at 9:21 PM
$AEON FDA broad approval coming for USA …already selling ABP 450 though European partner $EOLS THIRD DAY TO HIT $1.20…
0 · Reply
Mandi63
Mandi63 Oct. 14 at 3:20 PM
0 · Reply
Mandi63
Mandi63 Oct. 14 at 2:00 PM
$AEON $SANA $LENZ $EOLS $FEMY Aeon has hit $1.20 last two trading days…will continue to move upward as FDA approval approaches… BUY AND HOLD SMALL FLOAT 9 million public… $3.00-5.00
0 · Reply
Mandi63
Mandi63 Oct. 14 at 1:42 PM
0 · Reply
lknite
lknite Oct. 13 at 4:01 AM
$EOLS see ya back at $12
0 · Reply
PremarketAnalysis
PremarketAnalysis Oct. 10 at 11:40 PM
$EOLS SignalEngine: Bullish 80/20, Algo Vol 78%, Org Vol 22%, BRX 20%. Algo Intent: constructive recovery forming.. momentum rebuilding through steady bid support. Momentum Feed: https://premarketanalysis.com/#momentum=EOLS
0 · Reply
Mandi63
Mandi63 Oct. 10 at 1:55 PM
$AEON ABP 450 is already being sold though their European partner $EOLS worldwide..FDA approval in USA coming..new CEO YEARS OF experienced in BIOTECH
0 · Reply
Estimize
Estimize Oct. 9 at 11:06 AM
Wall St is expecting -0.15 EPS for $EOLS Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/eols?chart=historical&metric_name=eps&utm_c
0 · Reply
Longboardsoul
Longboardsoul Oct. 1 at 5:17 PM
$EOLS This stock is aids
0 · Reply
Damian23
Damian23 Sep. 25 at 3:49 PM
$EOLS I did again my calculation , I think they could need more money so I assumed 15% dilution, the consumer sentiment with the tariffs is not good right now: Peak sales target 2027: $495 million. Conservative 2x peak sales EV: 2×495=990 2×495=990 million USD. Shares outstanding Sept 2025: 64.7 million. Assuming 15% dilution → 74.5 million diluted shares. Cash on hand Q2 2025: $61.7 million. Debt outstanding: $155 million. Cash raised from dilution (9.7 million shares × $6): $58.2 million. Total cash = $61.7M + $58.2M = $119.9 million. Adjusted EV considering debt: $990M + $155M (debt) - $119.9M (cash) = $1,025.1 million. Equity value = EV - debt + cash = $1,025.1 million - $155 million + $119.9 million = $990 million Fair value per share = $990 million / 74.5 million = approx $13.29 per share. Current share price approx $6, 8I assumed they dillut at currentl evels) EV/Sales ratio with $300 million 2025 revenue = 995m/300m=3.3× 995m/300m=3.3×, aligned with aesthetics growth peers.
1 · Reply
lknite
lknite Sep. 23 at 4:41 PM
$EOLS /me gives eols a warm loving smile
0 · Reply